Amitha Shetty

Dr. Amitha Shetty

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RCRompicherla Narayana Charyulu
Rompicherla Narayana Charyulu
PJPunam Joshi
Punam Joshi
ASAmitha Shetty
Amitha Shetty
KSkalvatala sudhakar
kalvatala sudhakar
HAHAWRAZ MOHAMMED AMIN
HAWRAZ MOHAMMED AMIN
NANaif Alhumeed
Naif Alhumeed
Topical treatments are a potential therapeutic option for the therapy of osteoarthritis, with significant data supporting the effectiveness and safety of topical formulation. Topical gel formulations may offer an alternative to oral formulations to relieve osteoarthritis (OA) pain while decreasing systemic exposure. Topical capsaicin transemulgel may represent an effective and safe alternative. The transemulgel was prepared from aqueous Aloe vera gel and Carbopol 934 with capsaicin in clove oil emulsion. The optimized transemulgel of capsaicin showed a pH of 6.1 ± 0.1 and viscosity of 15263–998 cps. Data from in vitro diffusion demonstrated improved permeability properties. The formulation caused no skin irritation when applied topically. The optimal transemulgel spreadability was found to be 20.23 g·cm/s. In vitro and ex vivo studies of the optimized formulation were performed. The skin irritant test was performed on rat skin with an optimized and marketed formulation. Both showed no irritation on the skin. The transemulgel of the capsaicin with Aloe vera gel was proven to be effective for osteoarthritis therapy.

3 October 2021 in Asian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
ADAkhilesh Dubey
Akhilesh Dubey
CLCynthia Lizzie Lobo
Cynthia Lizzie Lobo
RGRavi Gs
Ravi Gs
ASAmitha Shetty
Amitha Shetty
SHSrinivas Hebbar
Srinivas Hebbar
SESally A. El‑Zahaby
Sally A. El‑Zahaby
The spread of SARS-CoV-2 as an emerging novel coronavirus disease (COVID-19) had progressed as a worldwide pandemic since the end of 2019. COVID-19 affects firstly lungs tissues which are known for their very slow regeneration. Afterwards, enormous cytokine stimulation occurs in the infected cells immediately after a lung infection which necessitates good management to save patients. Exosomes are extracellular vesicles of nanometric size released by reticulocytes on maturation and are known to mediate intercellular communications. The exosomal cargo serves as biomarkers in diagnosing various diseases; moreover, exosomes could be employed as nanocarriers in drug delivery systems. Exosomes look promising to combat the current pandemic since they contribute to the immune response against several viral pathogens. Many studies have proved the potential of using exosomes either as viral elements or host systems that acquire immune-stimulatory effects and could be used as a vaccine or drug delivery tool. It is essential to stop viral replication, prevent and reverse the massive storm of cytokine that worsens the infected patients’ situations for the management of COVID-19. The main benefits of exosomes could be; no cells will be introduced, no chance of mutation, lack of immunogenicity and the damaged genetic material that could negatively affect the recipient is avoided. Additionally, it was found that exosomes are static with no ability for in vivo reproduction. The current review article discusses the possibilities of using exosomes for detecting novel coronavirus and summarizes state of the art concerning the clinical trials initiated for examining the use of COVID-19 specific T cells derived exosomes and mesenchymal stem cells derived exosomes in managing COVID-19.

8 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMManohar M
Manohar M
Akhilesh DubeyAkhilesh Dubey
Akhilesh Dubey
ASAmitha Shetty
Amitha Shetty
Diabetes mellitus (D.M.) is a metabolic disease that has affected over 500 million people globally. Bioactive compounds such as β-carotene and Quercetin have gained research interest for their potential antidiabetic properties, and bioactives have reported superior combinatorial effects in several ailments, including D.M. However, poor oral bioavailability has limited their potential application. Thus, the present study was focused on developing ultrasonically fabricated β-Carotene nanoemulsion (βC-NE) by employing capmul as the oil phase, Gelucire 44/14 as surfactant and Acconon MCM C8 as co-surfactant. The 3 factor- 3 level Box-Behnken design (BBD) was applied to optimise the βC-NE and study the impact of selected independent variables such as % Smix (5 to 9%), amplitude (20–30%) and sonication time (2.5–7.5 min) on responses including globule size (G.S.), poly dispersibility Index (PDI) and entrapment efficiency (E.E.). Further, the combinatorial effect of βC-NE with Quercetin Nanoemulsion (QU-NE) in the streptozotocin-induced diabetic rat model was evaluated. The results exhibited that 7% Smix at 25% amplitude for 5 min produced βC-NE with a droplet size of 153.1 ± 12.25 nm, 0.200 ± 0.04 PDI, and 73.25 ± 3.25% E.E. The βC-NE showed superior in-vivo bioavailability by 5.38 folds. The βC-NE, combined with QU-NE, exhibited potential therapeutic benefits in controlling body weight, blood sugar level, lipid levels, and tissue damage markers. Additionally, the pancreatic cells and hepatic cells were well protected. These results demonstrate the potential benefits of βC-NE and QU-NE in combination and recommend them as a substitute strategy for diabetes.

9 September 2025 in Nutrition Reviews
Verified
Journal Article
Closed access
ASAmitha Shetty
Amitha Shetty
ADAkhilesh Dubey
Akhilesh Dubey
VRViona Princia Rodrigues
Viona Princia Rodrigues
SKSwathi Kamath
Swathi Kamath
LFLowel Fernandes
Lowel Fernandes
SHSrinivas Hebbar
Srinivas Hebbar
Pomegranate (Punica granatum L) is a rich source of bioactive compounds, including punicalagin, ellagic acid, anthocyanins, and urolithins, which contribute to its broad pharmacological potential. This review summarizes evidence from in vitro and in vivo experiments, as well as clinical studies, highlighting pomegranate’s therapeutic effects in inflammation, metabolic disorders, cancer, cardiovascular disease, neurodegeneration, microbial infections, and skin conditions. Mechanistic insights show modulation of pathways such as nuclear factor–kappa B (NF-κB), mitogen-activated protein kinase (MAPK), alpha serine/threonine-protein kinase (AKT1), and nuclear factor erythroid 2–related factor 2 (Nrf2). Notably, punicalagin exhibits antifungal activity via sterol 14-demethylase P450 (CYP51) inhibition, supported by molecular docking studies. While evidence supports the promising bioactivity of pomegranate compounds, their clinical application is hindered by low and variable bioavailability, inconsistent dosing and formulations, and limited data on adverse effects largely due to interindividual differences in gut microbiota metabolism of punicalagin into urolithins. Although pomegranate demonstrates an excellent safety profile with minimal reported adverse events, further long-term, well-designed clinical trials are essential to validate its efficacy, determine optimal dosing, and enable standardized therapeutic use. This review contributes to the discourse on the medicinal value of pomegranate, offering a comprehensive understanding of its role in addressing diverse health conditions and highlighting the importance of integrating medicinal plants such as pomegranate into modern nutrition and clinical practice.

25 February 2023
Verified
Preprint
Open access
PDF file
ASAmitha Shetty
Amitha Shetty
Akhilesh DubeyAkhilesh Dubey
Akhilesh Dubey
AMAlafiya Matcheswala
Alafiya Matcheswala
SBShilpa Bangera
Shilpa Bangera
After a drug is granted a marketing license, its post-marketing surveillance is evaluated to ensure that it is continuously monitored for undesirable effects. This monitoring is achieved through an effective Pharmacovigilance system. In our review, we discuss the Pharmacovigilance systems of Europe, the United States, and India, along with several examples of effective Pharmacovigilance strategies, such as the Tracleer® Access Programme and Tracleer® Excellence programs for Bosentan, Merck’s Worldwide Adverse Experience System, the European and United States Varicella Zoster Virus Identification Programs for Varivax, the Siddha Initiative for Documentation of Drug Adverse Reaction, an android mobile app for AYUSH Pharmacovigilance, and the Global Pharmacovigilance Database by Sanofi Pasteur. This report demonstrates the importance of post-marketing surveillance in detecting rare adverse experiences that may go unnoticed during clinical trials. It also emphasizes the significance of highlighting the field of Pharmacovigilance to improve patient safety and offer them the best possible quality of life.

12 September 2024
Verified
Book Chapter
Closed access
PDF file
Akhilesh DubeyAkhilesh Dubey
Akhilesh Dubey
ASAmitha Shetty
Amitha Shetty
MMManohar M
Manohar M
PJPraneetha Jain
Praneetha Jain